Business Context and Reporting Period
Expion360 Inc. (XPON), an emerging growth company incorporated in Nevada, filed this Form 8-K on October 16, 2025. The filing reports a material definitive agreement involving a private placement of equity securities and significant changes to executive leadership and the Board of Directors.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company closed a private placement on October 16, 2025, selling 613,077 shares of Common Stock and a pre-funded warrant for 144,498 shares.
- Offering Prices: Common Stock was sold at $1.65 per share; Pre-Funded Warrants were sold at $1.6499 per share.
- Net Proceeds: Approximately $1.1 million after deducting estimated offering expenses.
- Use of Proceeds: Funds are designated to pay severance obligations to former executive officers and for working capital and general corporate purposes.
- Debt and Liquidity: The filing does not provide specific data on total debt, cash balances, or liquidity ratios outside of the new proceeds.
Material Changes and Executive Leadership
The filing details a complete overhaul of the Company's top leadership, effective immediately on October 16, 2025:
- Resignations: Brian Schaffner resigned as Chief Executive Officer (CEO) and Paul Shoun resigned as President and Chairman of the Board. Both resignations are not the result of any disagreement with the Company.
- Severance Packages:
- Mr. Schaffner: Received a lump sum equal to 24 months of base salary and 100,000 fully vested Restricted Stock Units (RSUs). He will provide consulting services through January 31, 2026.
- Mr. Shoun: Received a lump sum equal to 24 months of base salary and 100,000 fully vested RSUs.
- Appointments:
- Joseph Hammer: Appointed CEO and Chairman of the Board. He will receive an annual base salary of $330,000 plus potential bonuses and equity awards. He is also the advisor to the lead investor, Pioneer Capital Anstalt.
- Scott Burell: Appointed as an Independent Director and member of the Compensation Committee. He brings over two decades of healthcare finance experience.
Outlook, Risks, and Contingencies
The Company expects to utilize the $1.1 million in net proceeds to fund the aforementioned severance payments and general working capital. The filing notes that the issuance of securities was made pursuant to Section 4(a)(2) of the Securities Act and Rule 506. No specific forward-looking guidance regarding revenue or profitability was provided in this filing. The primary risk highlighted is the transition of leadership and the immediate cash outflow required for executive severance.
Investor Verification Checklist
- Verify the total cash outflow for severance payments to Mr. Schaffner and Mr. Shoun to assess the immediate impact on the $1.1 million net proceeds.
- Confirm the vesting schedule and valuation of the 200,000 total RSUs granted to the departing executives.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any additional covenants or restrictions imposed by the new investors.
- Monitor the Company's cash runway given the stated use of proceeds for working capital and severance.
- Assess the strategic fit of Joseph Hammer's background in family office investing and his relationship with the lead investor.